The report is available by section, and can be customized to specific information needs and budget.The report examines key trends in the U.S., five major European countries (France, Germany, Italy, Japan, UK) and Japan; reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for over 100 infectious disease tests by assay, market segment, and country; provides test volume estimates by method (molecular, serology/immunodiagnostics, culture/microscopy); profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers.
This comprehensive seven-country report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding microbiology testing market, in evaluating emerging opportunities and developing effective business strategies.
Microbiology testing is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers during this decade. Among the main driving forces is continuing spread of AIDS, which remains the world’s major health threat and a key factor contributing to the rise of opportunistic infections; threat of bioterrorism; advances in molecular diagnostic technologies; and a wider availability of immunosuppressive drugs.
Although for some infections the etiology is still a mystery, while for others the causative microorganisms are present in minute concentrations long before the occurrence of first clinical symptoms, recent advances in genetic engineering and detection technologies are creating exciting opportunities for highly sensitive, specific and cost-effective products.
Worldwide Market Overview
- Estimated universe of laboratories performing
- Test volume and sales projections for major
Opportunities and Strategic Recommendations
- Emerging opportunities for new instrumentation,
appeal during the next five years.
- Design criteria for decentralized testing products.
- Alternative market penetration strategies.
- Potential market entry barriers and risks.
AIDS/HIV, Adenovirus, Aeromonads, Bartonella, Blastocystis Hominis, Campylobacter, Candida, Carbapenemase, Chancroid, Chlamydia, Clostridium, Coronavirus, Coxsackievirus, Cryptosporidium, Cyclospora, CMV, E. Coli, Echovirus, Encephalitis, Enterovirus, EBV, Giardia, Gonorrhea, Granuloma Inguinale, Hantavirus, H. Pylori, Hepatitis, Herpes, Influenza, Legionella, Lyme Disease, Lymphogranuloma, Malaria, Measles, Meningitis, Microsporidium, Mononucleosis, Mumps, Mycoplasma, Norovirus, HPV, Parvovirus, Pneumonia, Polyomaviruses, Pseudomonas, Rabies, RSV, Rhinovirus, Rotavirus, Rubella, Salmonella, Septicemia, Shigella, Staphylococci, Streptococci, Syphilis, Toxoplasmosis, Trichomonas, TB, Vibrio, West Nile, Yersinia.
France, Germany, Italy, Japan, Spain, UK, US
Market Segmentation Analysis
- Sales and market shares of major suppliers
- Volume and sales forecasts for over 100 infectious disease
° Blood Banks
° Commercial/Private Laboratories
° Physician Offices/Group Practices
° Public Health Laboratories
- Test volume estimates by method (molecular, serology/immunodiagnostics,
- Review of the market dynamics, trends, structure, size, growth
Current and Emerging Products
- In-depth examination of over 100 major diseases,
vaccines, drugs and market needs.
- Review of major analyzers used for infectious disease
characteristics, features and selling prices.
- Assessment of molecular diagnostic, monoclonal antibody,
applications for infectious disease testing.
- Global listings of companies developing or
by individual test.
- Strategic assessments of major suppliers and
portfolios, marketing tactics, collaborative
arrangements and new products in R&D.
Contains 1,954 pages and 824 tables
- Beckman Coulter/Danaher
- Becton Dickinson
- Eiken Chemical
- Elitech Group
- Enzo Biochem
- GSK Biologicals
- Leica Biosystems
- Ortho-Clinical Diagnostics
- Siemens Healthineers
- Takara Bio
- Thermo Fisher